

Notice reference number: [0803.17.08](#)

Notice date: 2/08/2017

[What's this about?](#)

Effective date: 2/08/2017

<input checked="" type="radio"/> ASX Trade	<input type="radio"/> ASX 24	<input type="radio"/> ASX TECH				
<input checked="" type="radio"/> Trading	<input type="radio"/> Clearing	<input type="radio"/> Settlement	<input type="radio"/> ALC	<input type="radio"/> ASX NET		
<input type="radio"/> Operations	<input type="radio"/> Technology	<input type="radio"/> Market Data	<input type="radio"/> Rules	<input checked="" type="radio"/> Compliance	<input type="radio"/> Risk	<input type="radio"/> Other

Title

Sienna Cancer Diagnostics Limited – Admission and Commencement of Official Quotation

Description

Sienna Cancer Diagnostics Limited (the “Company”) was admitted to the Official List of ASX Limited (ASX) on Wednesday, 2 August 2017.

Official quotation of the Company’s securities will commence at 11:00am AEST on Thursday, 3 August 2017. The Company has raised \$4,597,600 pursuant to the offer under its prospectus dated 25 May 2017 (the “Prospectus”), by the issue of 22,988,000 ordinary shares each fully paid at \$0.20.

Quoted Securities: 155,835,698 fully paid ordinary shares

ASX Code: SDX

Time: 11:00am, AEST

Date: Thursday, 3 August 2017

ASX Trade Abbreviation: SIENNA

ISIN: AU000000SDX1

Home Branch: Melbourne

Industry Classification: 3520 – Biotechnology

Registered Office: 1 Dalmore Drive
Scoresby VIC 3179
Phone: 03 8288 2141
Website: siennadiagnostics.com.au

Corporate Office: As above

Company Secretary: Tony Di Pietro

Share Registry: Link Market Services
Tower 4, 727 Collins Street
Melbourne VIC 3000
Phone: 1300 554 474

Balance Date: 30 June

CHESS:	Participating. The Company will also operate an issuer sponsored sub-register.
Place of Incorporation:	New South Wales
Dividend Policy:	Refer to section 4 of the Company's Prospectus.
Activities:	Diagnostic technologies in detection, characterisation and monitoring of cancer.
ASX Restricted Securities:	<p>24,426,629 fully paid ordinary shares, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of official quotation.</p> <p>2,000,000 options exercisable at \$0.22 expiring 27 September 2018, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of official quotation.</p> <p>2,500,000 options exercisable at \$0.243 expiring 1 April 2022, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of official quotation.</p>
Securities not quoted:	<p>2,273,314 options exercisable at \$0.22 on or after 2 April 2018 expiring on 2 October 2018.</p> <p>1,500,000 options exercisable at \$0.22 expiring 3 February 2018.</p> <p>4,530,000 options exercisable at \$0.22 with varying vesting and expiry dates with the last expiry date being 1 April 2022.</p>

[What do I need to do and by when?](#)

For further details, please refer to the Company's Prospectus.

[Need more information?](#)

For further details, please refer to the Company's Prospectus.

Issued by

John Johansson, Senior Adviser, Listing Compliance (Melbourne)

Contact Details

(03) 9617 8770

Disclaimer
